Our Tests


Also known as: t(9;11) FISH, MLLT3-MLL FISH

« Back to test list


Chromosomal rearrangements affecting chromosome 11q23 result in fusion of the MLL gene (also known as KMT2A) with multiple different fusion partners. One of the most common fusion partners is MLLT3, located at chromosome 9p22. Presence of a MLL-MLLT3 fusion gene defines a specific AML subtype. This gene fusion is the result of a chromosomal translocation: t(9;11)(p22;q23).

The identification of this gene fusion has diagnostic and prognostic implications.

Clinical Utility

Fusion of MLL and MLLT3 is associated with intermediate prognosis. Other rearrangements involving MLL have a less favourable prognosis.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes designed to detect MLL-MLLT3 gene fusion.

Test Ordering

This test is usually requested by a haematologist or oncologist.

0.5 mL bone marrow in transport media (or 10 mL blood in lithium heparin if blasts>10%).

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.



This test may have a rebate for all or part of the cost.

Medicare Rebate

This test has a Medicare rebate of $196.35, subject to the requirements of the Medicare descriptor being met. The MBS item number is 73314.

Turnaround Time

2 working days.